About La Jolla Pharmaceutical (NASDAQ:LJPC)
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It offers GIAPREZA, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. The company is developing LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LJPC
CUSIPN/A
Phone858-207-4264
Debt
Debt-to-Equity RatioN/A
Current Ratio5.07%
Quick Ratio5.07%
Price-To-Earnings
Trailing P/E Ratio-5.59
Forward P/E Ratio-6.12
P/E GrowthN/A
Sales & Book Value
Annual Sales$620,000.00
Price / Sales1,272.03
Cash FlowN/A
Price / CashN/A
Book Value$3.68 per share
Price / Book8.22
Profitability
EPS (Most Recent Fiscal Year)($5.41)
Net Income$-114,800,000.00
Net MarginsN/A
Return on Equity-94.86%
Return on Assets-81.11%
Miscellaneous
Employees309
Outstanding Shares26,080,000
La Jolla Pharmaceutical (NASDAQ:LJPC) Frequently Asked Questions
What is La Jolla Pharmaceutical's stock symbol?
La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."
How were La Jolla Pharmaceutical's earnings last quarter?
La Jolla Pharmaceutical (NASDAQ:LJPC) posted its earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.25) by $0.49. View La Jolla Pharmaceutical's Earnings History.
When is La Jolla Pharmaceutical's next earnings date?
What price target have analysts set for LJPC?
7 analysts have issued twelve-month price targets for La Jolla Pharmaceutical's shares. Their forecasts range from $20.00 to $100.00. On average, they anticipate La Jolla Pharmaceutical's share price to reach $58.6667 in the next year. View Analyst Ratings for La Jolla Pharmaceutical.
What are Wall Street analysts saying about La Jolla Pharmaceutical stock?
Here are some recent quotes from research analysts about La Jolla Pharmaceutical stock:
- 1. According to Zacks Investment Research, "LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. " (4/17/2018)
- 2. Chardan Capital analysts commented, "We see La Jolla Pharmaceutical as a remarkably de-risked rare disease story, and thus one deserving of higher conviction now, than the high conviction we had a year ago. With our 24 January 2017 research, we made La Jolla a Chardan Top Pick for 2017 based on (1) La Jolla’s approach being one of the more compelling and convincing rare disease strategies in biotech…[due to] focusing on naturally-occurring peptides with well-established biological functions" and (2) confidence the company will produce positive [pivotal Giapreza] ATHOS-3 phase III results" in 1Q17." (1/25/2018)
- 3. Cowen Inc analysts commented, "LJPC reported Q1 financials." (4/28/2017)
Who are some of La Jolla Pharmaceutical's key competitors?
Some companies that are related to La Jolla Pharmaceutical include Atara Biotherapeutics (ATRA), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD), Iovance Biotherapeutics (IOVA), DBV Technologies (DBVT), Cellectis (CLLS), REGENXBIO (RGNX), Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR), Bavarian Nordic (BVNRY), Coherus BioSciences (CHRS), Novavax (NVAX), Jounce Therapeutics (JNCE), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), Heska (HSKA), Mesoblast (MESO) and EntreMed (CASI).
Who are La Jolla Pharmaceutical's key executives?
La Jolla Pharmaceutical's management team includes the folowing people:
- Dr. George F. Tidmarsh, Pres, CEO, Sec. & Director (Age 58)
- Mr. Dennis M. Mulroy, CFO & Principal Accounting Officer (Age 63)
- Ms. Jennifer A. Carver MBA, Chief Operating Officer (Age 64)
- Dr. Lakhmir S. Chawla M.D., Chief Medical Officer (Age 47)
- Mr. James M. Rolke, Chief Scientific Officer (Age 49)
Has La Jolla Pharmaceutical been receiving favorable news coverage?
News coverage about LJPC stock has been trending somewhat positive this week, Accern reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. La Jolla Pharmaceutical earned a media sentiment score of 0.13 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 46.72 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are La Jolla Pharmaceutical's major shareholders?
La Jolla Pharmaceutical's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include
TANG CAPITAL PARTNERS LP
(16.50%),
PRUDENTIAL FINANCIAL INC
(10.90%) and BLACKROCK INC. (4.60%). Company insiders that own La Jolla Pharmaceutical stock include Dennis Mulroy, George F Tidmarsh, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Laura L Douglass, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Institutional Ownership Trends for La Jolla Pharmaceutical.
How do I buy shares of La Jolla Pharmaceutical?
Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is La Jolla Pharmaceutical's stock price today?
One share of LJPC stock can currently be purchased for approximately $30.24.
How big of a company is La Jolla Pharmaceutical?
La Jolla Pharmaceutical has a market capitalization of $822.22 million and generates $620,000.00 in revenue each year. The biopharmaceutical company earns $-114,800,000.00 in net income (profit) each year or ($5.41) on an earnings per share basis. La Jolla Pharmaceutical employs 309 workers across the globe.
How can I contact La Jolla Pharmaceutical?
La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-207-4264 or via email at [email protected]
MarketBeat Community Rating for La Jolla Pharmaceutical (LJPC)
MarketBeat's community ratings are surveys of what our community members think about La Jolla Pharmaceutical and other stocks. Vote "Outperform" if you believe LJPC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LJPC will underperform the S&P 500 over the long term. You may vote once every thirty days.
La Jolla Pharmaceutical (NASDAQ:LJPC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for La Jolla Pharmaceutical in the last 12 months. Their average twelve-month price target is $58.6667, suggesting that the stock has a possible upside of 94.00%. The high price target for LJPC is $100.00 and the low price target for LJPC is $20.00. There are currently 2 sell ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Buy | Buy |
| Consensus Rating Score: | 2.43 | 2.43 | 2.71 | 3.00 |
| Ratings Breakdown: | 2 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $58.6667 | $60.00 | $60.1667 | $54.60 |
| Price Target Upside: | 94.00% upside | 62.91% upside | 85.41% upside | 57.74% upside |
La Jolla Pharmaceutical (NASDAQ:LJPC) Consensus Price Target History
La Jolla Pharmaceutical (NASDAQ:LJPC) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
La Jolla Pharmaceutical (NASDAQ:LJPC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
La Jolla Pharmaceutical (NASDAQ LJPC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 25.47%
Institutional Ownership Percentage: 96.29%
La Jolla Pharmaceutical (NASDAQ LJPC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/15/2018 | Kevin C Tang | Director | Buy | 508,474 | $29.50 | $14,999,983.00 | |  |
| 3/15/2018 | Perceptive Advisors Llc | Major Shareholder | Buy | 700,000 | $29.50 | $20,650,000.00 | | |
| 3/2/2018 | Kevin C Tang | Director | Buy | 10,000 | $30.44 | $304,400.00 | | |
| 2/27/2018 | Kevin C Tang | Director | Buy | 150,000 | $31.82 | $4,773,000.00 | | |
| 2/23/2018 | Jennifer Carver | COO | Buy | 1,000 | $32.48 | $32,480.00 | 5,500 | |
| 2/14/2018 | Life Sciences Maste Perceptive | Major Shareholder | Buy | 175,000 | $32.72 | $5,726,000.00 | | |
| 12/29/2017 | Laura L Douglass | Director | Sell | 10,000 | $32.32 | $323,200.00 | | |
| 12/29/2017 | Laura L Douglass | Director | Sell | 10,000 | $32.32 | $323,200.00 | 6,000 | |
| 12/27/2017 | Jennifer Carver | COO | Buy | 1,000 | $33.22 | $33,220.00 | 4,500 | |
| 12/27/2017 | Jennifer Carver | COO | Buy | 1,000 | $33.22 | $33,220.00 | 4,500 | |
| 3/23/2017 | Kevin C Tang | Director | Buy | 149,254 | $33.50 | $5,000,009.00 | | |
| 3/3/2017 | Dennis Mulroy | CFO | Buy | 500 | $33.95 | $16,975.00 | 500 | |
| 3/3/2017 | George F Tidmarsh | CEO | Buy | 3,000 | $34.17 | $102,510.00 | 1,353,086 | |
| 3/3/2017 | Lakhmir S Chawla | Insider | Buy | 1,600 | $34.80 | $55,680.00 | 1,085 | |
| 9/13/2016 | Kevin C Tang | Director | Buy | 139,035 | $19.82 | $2,755,673.70 | | |
| 3/4/2016 | Kevin C Tang | Director | Buy | 20,000 | $19.85 | $397,000.00 | | |
| 3/1/2016 | George F Tidmarsh | CEO | Buy | 2,000 | $16.57 | $33,140.00 | 1,424,086 | |
| 9/28/2015 | Lakhmir S Chawla | Insider | Buy | 485 | $27.75 | $13,458.75 | 485 | |
| 9/10/2015 | Kevin C Tang | Director | Buy | 80,000 | $38.00 | $3,040,000.00 | | |
| 8/21/2015 | Kevin C Tang | Director | Buy | 170,000 | $27.11 | $4,608,700.00 | | |
| 6/26/2015 | Kevin C Tang | Director | Buy | 110,000 | $23.58 | $2,593,800.00 | | |
| 6/24/2015 | Kevin C Tang | Director | Buy | 220,000 | $22.23 | $4,890,600.00 | | |
| 6/23/2015 | Kevin C Tang | Director | Buy | 53,836 | $22.27 | $1,198,927.72 | | |
| 6/22/2015 | Kevin C Tang | Director | Buy | 77,850 | $21.41 | $1,666,768.50 | | |
| 5/13/2015 | Kevin C Tang | Director | Buy | 190,583 | $18.24 | $3,476,233.92 | | |
| 5/12/2015 | George F Tidmarsh | CEO | Buy | 4,000 | $18.37 | $73,480.00 | | |
| 12/15/2014 | Kevin C Tang | Director | Buy | 232,343 | $12.84 | $2,983,284.12 | | |
| 12/11/2014 | George F Tidmarsh | CEO | Buy | 4,000 | $11.38 | $45,520.00 | | |
| 9/26/2014 | George F Tidmarsh | CEO | Buy | 2,000 | $9.35 | $18,700.00 | | |
| 9/26/2014 | Kevin C Tang | Director | Buy | 169,555 | $9.14 | $1,549,732.70 | | |
| 9/25/2014 | Kevin C Tang | Director | Buy | 30,500 | $9.17 | $279,685.00 | | |
| 9/24/2014 | Kevin C Tang | Director | Buy | 95,000 | $9.10 | $864,500.00 | | |
| 9/18/2014 | George F Tidmarsh | CEO | Buy | 5,000 | $9.18 | $45,900.00 | | |
| 7/23/2014 | George F Tidmarsh | CEO | Buy | 19,000 | $10.50 | $199,500.00 | | |
| 5/21/2014 | George Tidmarsh | CEO | Buy | 12,000 | $7.37 | $88,440.00 | 1,391,086 | |
| 4/14/2014 | George Tidmarsh | CEO | Buy | 8,000 | $9.53 | $76,240.00 | 1,391,086 | |
| 2/7/2014 | George F Tidmarsh | CEO | Buy | 3,000 | $7.25 | $21,750.00 | | |
(Data available from 1/1/2013 forward)
La Jolla Pharmaceutical (NASDAQ LJPC) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Zacks Investment Research Lowers La Jolla Pharmaceutical (LJPC) to Hold
www.americanbankingnews.com - April 17 at 9:48 PM |
| La Jolla Pharmaceutical (LJPC) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 17 at 8:17 AM |
| La Jolla Pharmaceutical (LJPC) Rating Reiterated by Jefferies Group
www.americanbankingnews.com - April 16 at 12:37 PM |
| La Jolla Pharmaceutical (LJPC) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 15 at 4:07 PM |
| La Jolla Pharmaceutical (LJPC) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - April 13 at 4:23 PM |
| La Jolla Pharmaceutical (LJPC) Raised to Hold at BidaskClub
www.americanbankingnews.com - April 11 at 9:31 PM |
| La Jolla Pharmaceutical (LJPC) Upgraded at ValuEngine
www.americanbankingnews.com - April 10 at 12:33 AM |
| La Jolla Pharmaceutical (LJPC) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 7 at 7:17 PM |
| La Jolla Pharmaceutical (LJPC) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 10:54 AM |
| La Jolla Pharmaceutical Sees Unusually Large Options Volume (LJPC)
www.americanbankingnews.com - April 4 at 8:07 AM |
| La Jolla Pharmaceutical (LJPC) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - April 3 at 12:44 PM |
| La Jolla Pharmaceutical (LJPC) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 2 at 6:26 PM |
| La Jolla Pharmaceutical (LJPC) Downgraded by BidaskClub
www.americanbankingnews.com - March 29 at 4:10 PM |
| La Jolla Pharmaceutical (LJPC) Upgraded at BidaskClub
www.americanbankingnews.com - March 26 at 11:30 PM |
| La Jolla Pharmaceutical (LJPC) Major Shareholder Buys $20,650,000.00 in Stock
www.americanbankingnews.com - March 26 at 10:28 PM |
| BidaskClub Lowers La Jolla Pharmaceutical (LJPC) to Sell
www.americanbankingnews.com - March 24 at 8:23 PM |
 | BRIEF-La Jolla PharmaAnnounces Launch Of Giapreza In United States
www.reuters.com - March 23 at 8:47 AM |
 | La Jolla Pharma launches Giapreza in U.S.
seekingalpha.com - March 23 at 8:47 AM |
| Investors Purchase High Volume of Put Options on La Jolla Pharmaceutical (LJPC)
www.americanbankingnews.com - March 23 at 7:04 AM |
| La Jolla Pharmaceutical (LJPC) Price Target Cut to $83.00 by Analysts at HC Wainwright
www.americanbankingnews.com - March 22 at 8:12 PM |
 | La Jolla Pharmaceutical (LJPC) Announces Launch of GIAPREZA in the United States - StreetInsider.com
www.streetinsider.com - March 22 at 5:14 PM |
 | La Jolla Pharmaceutical Company Announces Launch of GIAPREZA™ (angiotensin II) in the United States
finance.yahoo.com - March 22 at 5:14 PM |
| La Jolla Pharmaceutical (LJPC) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 21 at 3:49 PM |
| Kevin C. Tang Buys 508,474 Shares of La Jolla Pharmaceutical (LJPC) Stock
www.americanbankingnews.com - March 19 at 10:10 PM |
| La Jolla Pharma prices stock offering at $29.50; shares up 1% premarket
seekingalpha.com - March 15 at 8:41 AM |
| La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - March 15 at 8:41 AM |
| La Jolla Pharmaceutical (LJPC) to Offer $100M in Common Stock - StreetInsider.com
www.streetinsider.com - March 14 at 6:35 PM |
| La Jolla Pharmaceutical Company Announces $100 Million Public Offering of Common Stock
finance.yahoo.com - March 14 at 6:35 PM |
| La Jolla (LJPC) Says GIAPREZA Significantly Improved Survival, Reduced Time on Renal Replacement Therapy in Patients with Acute Kidney Injury
www.streetinsider.com - March 7 at 8:50 AM |
| GIAPREZA™ (angiotensin II) Significantly Improved Survival and Reduced Time on Renal Replacement Therapy in Patients with Acute Kidney Injury
finance.yahoo.com - March 6 at 5:22 PM |
| Sectoral Asset Management Inc Increases Stake in La Jolla Pharmaceutical (LJPC)
www.americanbankingnews.com - March 5 at 3:33 PM |
| Kevin C. Tang Acquires 10,000 Shares of La Jolla Pharmaceutical (LJPC) Stock
www.americanbankingnews.com - March 2 at 6:41 PM |
| La Jolla Pharmaceutical (LJPC) Shares Sold by Broadfin Capital LLC
www.americanbankingnews.com - March 2 at 5:08 AM |
| Ascend Capital LLC Invests $6.08 Million in La Jolla Pharmaceutical (LJPC) Stock
www.americanbankingnews.com - March 1 at 4:40 AM |
| Insider Buying: La Jolla Pharmaceutical (LJPC) COO Purchases 1,000 Shares of Stock
www.americanbankingnews.com - February 27 at 9:46 PM |
| Insider Buying: La Jolla Pharmaceutical (LJPC) Director Acquires 150,000 Shares of Stock
www.americanbankingnews.com - February 27 at 9:10 PM |
| La Jolla Pharma's Giapreza shows treatment benefit in late-stage study in patients with vasodilatory shock
seekingalpha.com - February 26 at 8:41 AM |
 | GIAPREZA™ (angiotensin II) Significantly Improved Survival of Patients with High APACHE II Scores in ATHOS-3 Study - GlobeNewswire (press release)
globenewswire.com - February 25 at 9:05 AM |
| GIAPREZA™ (angiotensin II) Significantly Improved Survival of Patients with High APACHE II Scores in ATHOS-3 Study
finance.yahoo.com - February 25 at 9:05 AM |
| La Jolla Pharmaceutical (LJPC) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 24 at 3:42 PM |
| La Jolla Pharmaceutical (LJPC) Issues Quarterly Earnings Results, Misses Estimates By $0.49 EPS
www.americanbankingnews.com - February 24 at 10:52 AM |
| La Jolla Pharmaceutical (LJPC) Reports Treatment of First Patient in ... - StreetInsider.com
www.streetinsider.com - February 23 at 8:48 AM |
| La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress
finance.yahoo.com - February 22 at 5:20 PM |
| Zacks: Analysts Anticipate La Jolla Pharmaceutical (LJPC) to Post -$1.25 Earnings Per Share
www.americanbankingnews.com - February 19 at 7:20 PM |
| La Jolla Pharmaceutical (LJPC) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - February 18 at 12:42 AM |
| La Jolla Pharmaceutical (LJPC) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - February 17 at 10:28 PM |
| La Jolla Pharmaceutical (LJPC) Major Shareholder Acquires $5,726,000.00 in Stock
www.americanbankingnews.com - February 15 at 9:10 PM |
| Q2 2018 Earnings Forecast for La Jolla Pharmaceutical (LJPC) Issued By Jefferies Group
www.americanbankingnews.com - February 14 at 8:20 AM |
| Jefferies Group Downgrades La Jolla Pharmaceutical (LJPC) to Underperform
www.americanbankingnews.com - February 12 at 10:46 PM |
| Jefferies Downgrades La Jolla On Weak Forecast For Blood Pressure Drug
finance.yahoo.com - February 12 at 4:01 PM |
La Jolla Pharmaceutical (NASDAQ:LJPC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
La Jolla Pharmaceutical (NASDAQ:LJPC) Income Statement, Balance Sheet and Cash Flow Statement
La Jolla Pharmaceutical (NASDAQ LJPC) Stock Chart for Thursday, April, 19, 2018
Loading chart…
